| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2142834 | Lung Cancer | 2010 | 6 Pages |
Abstract
The similar efficacy with acceptable safety, the ease of administration in out-patients and the economical advantages justify comparison of this oral chemotherapy with conventional intravenous chemotherapy. A randomised phase II trial is on-going in France for second-line SCLC patients on this theme.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Bernard Lebeau, Christos Chouaïd, Mariette Baud, Marie-Josée Masanès, Michel Febvre,